1	Redox imbalance and oxidative DNA damage during isoniazid treatment:
2	A clinical and translational pharmacokinetic study
3	
4	Isaac Zentner <sup>1</sup> , Hyun-moon Back <sup>2</sup> , Leonid Kagan <sup>2</sup> , Selvakumar Subbian <sup>1</sup> , Jyothi Nagajyothi <sup>1</sup> ,
5	Shashikant Srivastava <sup>3</sup> , Jotam Pasipanodya <sup>3</sup> , Tawanda Gumbo <sup>3</sup> , Gregory P. Bisson <sup>4</sup> , Christopher
6	Vinnard <sup>1</sup>
7	<sup>1</sup> Public Health Research Institute, New Jersey Medical School, Newark, NJ, USA
8	<sup>2</sup> Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA
9	<sup>3</sup> Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX, USA
10	<sup>4</sup> University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
11	
12	Corresponding author:
13	Christopher Vinnard, MD MPH MSCE
14	Public Health Research Institute
15	225 Warren Street
16	Newark, NJ 07103
17	christopher.vinnard@njms.rutgers.edu
18	
19	Abstract word count: 252
20	Word count: 4557
21	Number of tables: 3
22	Number of figures: 5
23	Number of supplemental figures: 1
24	Number of supplemental tables: 3
25	Number of references: 36

# 26 ABSTRACT

27 Background: The potential for hepatotoxicity during isoniazid-based tuberculosis (TB) treatment presents a major challenge for TB control programs worldwide. We sought to determine whether 28 pharmacokinetic exposures of isoniazid and its metabolites were related to cellular oxidation/reduction 29 30 status and downstream markers of oxidative DNA damage. 31 **Methods:** We performed intensive pharmacokinetic sampling among isoniazid-treated patients to determine the relative plasma exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine. 32 Physiologically-based pharmacokinetic modeling was used to estimate liver tissue exposures during a 33 34 24-hour dosing interval for each compound. We experimentally treated HepG2 cells with isoniazid and metabolites at equimolar concentrations corresponding to these exposures for 7, 14, and 28 day 35 periods, and performed assays related to redox imbalance and oxidative DNA damage at each 36 timepoint. We related a urine marker of oxidative DNA damage to serum isoniazid pharmacokinetic 37 38 exposures and pharmacogenetics in a clinical study. 39 **Results:** Among isoniazid-treated patients, serum concentrations of hydrazine and isoniazid concentrations were highly correlated. At equimolar concentrations that approximated hepatic tissue 40 exposures during a 24-hour dosing interval, hydrazine demonstrated the highest levels of redox 41 42 imbalance, mitochondrial injury, and oxidative DNA damage over a 28-day treatment period. In a clinical validation study of isoniazid-treated TB patients, peak isoniazid serum concentrations were 43 positively associated with a urine biomarker of oxidative DNA damage. 44

45 Conclusions: Isoniazid and its metabolites share the potential for oxidative cellular damage, with the 46 greatest effects observed for hydrazine. Future studies should investigate the clinical consequences of 47 oxidative stress with regards to clinical episodes of drug induced liver injury during isoniazid treatment.

48

# 49 BACKGROUND

The potential for isoniazid hepatotoxicity during tuberculosis (TB) treatment remains a major challenge for TB control efforts worldwide. In the United States, isoniazid is the second leading cause of druginduced liver injury, with evidence of under-reporting<sup>1</sup>. Aside from the direct effects of patient injury, the potential for hepatotoxicity during isoniazid treatment places additional burdens on TB control programs<sup>2</sup>, including laboratory monitoring and treatment interruptions, and hampers drug development efforts<sup>3</sup>. The risk of isoniazid-related hepatotoxicity is further increased in the setting of co-infection with human immunodeficiency virus (HIV)<sup>4</sup>.

57

A central challenge to understanding isoniazid hepatotoxicity has been its idiosyncratic nature, lacking 58 a clear relationship with dose size<sup>5</sup>. Damage mediated by reactive oxygen species (ROS), as a 59 consequence of imbalance between cellular oxidation and reduction<sup>6</sup>, is a key determinant of drug 60 61 hepatotoxicity<sup>7,8</sup>. The imbalance between oxidation and reduction processes overwhelms cellular stores of glutathione, which provides an intracellular sink for ROS directed by the glutathione-s-62 transferase (GST) family of proteins<sup>9</sup>. With its high cellular density of mitochondria, the liver is 63 64 particularly vulnerable to injury from ROS byproducts, leading to free radical-induced modifications of host proteins, DNA, and lipids<sup>10</sup>. 65

66

67 While there is abundant evidence that isoniazid and its metabolites cause redox imbalance in mammalian cells<sup>5,11,12</sup>, clinical studies have not yet linked isoniazid parent-metabolite pharmacokinetic 68 69 exposures with markers of oxidative stress. Hydrazine, an isoniazid metabolite that damages the 70 electron transport chain in mitochondria, has been proposed as a primary driver of isoniazid 71 hepatotoxicity, yet pre-clinical studies have evaluated concentrations higher than those achieved in 72 patients during isoniazid treatment. Establishing the link, if any, between markers of oxidative stress 73 and hepatotoxicity during isoniazid treatment could lead to alternate approaches to monitoring during treatment, personalization of isoniazid dosing, or the development of ameliorating therapeutic strategies 74

- <sup>75</sup> for toxicity prevention<sup>13</sup>. Here, we hypothesized that long-term exposures to isoniazid and its
- 76 metabolites were related to markers of redox imbalance in hepatocytes, and that hydrazine exposures
- 77 would drive redox imbalance and oxidative damage in the liver.
- 78
- 79 METHODS

80 <u>Clinical pharmacokinetic study to determine relative plasma exposures of isoniazid, acetylisoniazid,</u>

81 <u>hydrazine, and acetylhydrazine</u>

We performed intensive pharmacokinetic sampling for drug and metabolite concentrations in 10 TB 82 83 patients (4 latent infection patients and 6 active TB patients) treated with isoniazid, in order to identify the relevant metabolite concentrations for subsequent pre-clinical experiments. After an overnight fast, 84 patients were dosed with oral isoniazid (300 mg). A pre-dose blood draw was performed, with additional 85 blood draws at 1, 2, 4, 6, and 8 hours after dosing. Following centrifugation, plasma samples were 86 87 stored at -80C until shipment to Alturas Analytics (Moscow, ID) for analysis. At each timepoint, we 88 measured plasma concentrations of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine (Figure 1). Noncompartmental pharmacokinetic analysis was performed to determine area under the 89 concentration-versus-time curve (AUC), extrapolated over a 24-hour dosing interval according to the 90 91 slope defined in the elimination phase.

92

93 Physiologically-based pharmacokinetic model of liver tissue exposures of isoniazid and its metabolites 94 To predict the hepatic tissue exposures of isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine 95 during isoniazid treatment, the whole-body physiologically based pharmacokinetic model with advanced 96 compartmental and transit model in GastroPlus (Ver 9.7) was used (Supplementary Figure 1). All physicochemical properties for those substances were predicted based on chemical structure from a 97 98 built-in predictor in GastroPlus. Population-dependent physiological parameters, including tissue 99 volumes and perfusion rate in humans, were obtained using the Population Estimates for Age-Related Physiology module in GastroPlus (Supplementary Table 1). After simulating time-versus-concentration 100

profiles of substances in liver and plasma, noncompartmental pharmacokinetic analysis was performed
 to calculate the AUC<sub>0-24</sub> ratio between liver and plasma. This ratio was used to predict liver tissue
 exposures to isoniazid and metabolites, during a 24-hour dosing interval, based on the observed
 plasma exposures in the clinical study.

105

#### 106 *In vitro* pharmacologic exposures of hepatocytes to isoniazid and its metabolites

107 The human liver carcinoma cell line, HepG2, is highly differentiated and is often used to screen the cytotoxicity potential of new chemical entities early in drug development<sup>14</sup>. HepG2 cells were cultured in 108 109 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/ml streptomycin and 2mM L-glutamine, unless otherwise stated. Cells were 110 continuously incubated at 37°C in a humidified 5% CO2 / 95% air environment and plated in a 12-well 111 112 plate at 4x10<sup>5</sup> cells/well, over a duration of 24 hours prior to compound exposure. Compound stocks 113 dissolved in water were freshly made each exposure day. Cellular supernatant was replaced with 2 mL 114 of culture media containing 10 µM of compound and left to incubate until 90% confluency was reached. Cell passages were conducted every 3 days under continual exposure to the designated compound for 115 the indicated time period. Cellular supernatant was collected at each passage, clarified, aliquoted, and 116 117 stored at -80°C for future analysis. Treated cells and supernatants were then examined for markers of 118 cytotoxicity, mitochondrial toxicity, and oxidative DNA damage as described below.

119

#### 120 Free thiol availability assay

By serving as targets of ROS, thiols provide the cellular defense system against oxidative stress.

122 Glutathione is the principal non-protein thiol in most cells, and high intracellular glutathione

123 concentrations are required to maintain protein thiols in reduced states, which is essential for cellular

124 functions in metabolism, signaling, and detoxification<sup>15</sup>. Cellular glutathione depletion was quantified in

a free thiol availability assay<sup>16</sup>. Black 96-well polystyrene clear bottom plates were coated with 50

126 µg/mL of poly-d-lysine for 1 hour at 37°C. Following multiple washes with PBS, HepG2 cells from the

127	long-term low-exposure culture growth, at the indicated times, were plated at 3.3x10 <sup>5</sup> cells per well and
128	left to incubated at 37°C for 12 hours maintain compound exposure. ThiolTracker™ Violet dye
129	(ThermoFisher) was used to asses free thiol availability following the manufacturer's instructions.
130	Briefly, cells were washed two times with D-PBS +C/M prior to the addition of 20 $\mu$ M of ThiolTracker.
131	Following a 30 min incubation at 37°C, cells were washed three times with D-PBS +C/M. Fluorescent
132	intensity at 404nm <sub>Ex</sub> /526nm <sub>Em</sub> was measured on a Synergy H1 Hybrid Multi-Mode Reader (BioTek).
133	
134	Mitochondrial membrane integrity
135	To assess mitochondrial membrane integrity, black 96-well polystyrene clear bottom plates were coated
136	with 50 $\mu$ g/mL of poly-d-lysine for 1 hour at 37°C. Following multiple washes with PBS, HepG2 cells
137	from the long-term low-exposure culture growth, at the indicated times, were plated at 3.3x10 <sup>5</sup> cells per
138	well and left to incubated at 37°C for 12 hours maintaining compound exposure. Tetramethylrhodamine,
139	methyl ester (ThermoFisher, Waltham, Massachusetts) was added at 100 nM at 37°C for 30 minutes.
140	Following three washes with PBS, fluorescent intensity at $488 nm_{Ex}/570 nm_{Em}$ was measured on a
141	Synergy H1 Hybrid Multi-Mode Reader (BioTek).
142	
143	Cellular and mitochondrial toxicity
144	Mitochondrial toxicity analysis was assayed using the Mitochondrial ToxGlo Assay (Promega, Madison,
145	WI) following the manufacturer's instructions. Briefly, cells obtained from the long-term low-exposure
146	culture growth, at the indicated times, were grown in a 96-well flat clear bottom black polystyrene plate
147	at 3.3x10 <sup>5</sup> cells per well in glucose-free (galactose supplemented) culture media. Compound
148	concentrations (10 $\mu$ M) were consistently maintained throughout the experiment. Following a 24-hour
149	incubation with compound, cytotoxicity was evaluated by the addition of a fluoregenic peptide substrate,
150	bis-AAF-R110, to the cell supernatant for 30 minutes at 37°C. The bis-AAF-R110 substrate penetrates
151	compromised plasma membranes and is activated via interactions with necrosis-associated proteases.
152	After the cells were allowed to incubate for 30 minutes at 37°C, fluorescence intensity was measured at

485nm<sub>Ex</sub>/525nm<sub>Em</sub>. To evaluate mitochondrial toxicity, the plate was acclimated to room temperature for
5 minutes, at which point the ATP detection reagent was added. Cell lysis mixture was transferred to a
96-well flat solid white bottom plate and luminescence intensity was measured. Assays of fluorescence
and luminescence activity were performed with a Synergy H1 Hybrid Multi-Mode Reader (BioTek,
Winooski, VT).

158

# 159 Comet chip imaging of cellular DNA damage

Cells treated for 1 week with 10 µM of compound were plated onto a CometChip (Trevigen) at 2x10<sup>5</sup> 160 cells/mL in a single cell suspension<sup>17</sup>. Cells were incubated on the chip for 60 min at 37°C. The plate 161 was then gently washed with PBS and coated with 1% low melting agarose. After the agarose was 162 solidified by cooling at 4°C, the plate was washed with pre-chilled non-activated alkaline lysis buffer 163 164 (2.5 M NaCl, 100nM Na<sub>2</sub>EDTA, 10mM Tris, pH 10). The chip was lysed overnight at 4°C by submerging 165 the chip in the alkaline lysis buffer containing 1% Triton-X. The plate was then washed with PBS and 166 placed in an electrophoresis chamber filled with pre-chilled alkaline electrophoresis buffer (2mM Na<sub>2</sub> EDTA, 300 mM NaOH). Following a 40 min incubation at 4°C to allow for alkaline unwinding, 167 electrophoresis was carried out at 80 volts for 30 min at 4°C. The chip was then neutralized with two 168 169 incubations at 4°C in 400 mM Tris, pH 7.5 buffer, and equilibrated in 20 mM Tris, pH 7.4 at 4°C for 20 min. DNA staining was achieved by incubating the chip in 100 mL of 0.2X SYBR Gold overnight at 4°C. 170 Fluorescent images were acquired on an Evos FL Imaging System (ThermoFisher). 171

172

# 173 Immunofluorescence for $\gamma$ -H2Ax

H2Ax is a core histone protein found in the nucleosome, and the phosphorylation of H2Ax is a marker of DNA damage caused by ROS. Variant histone H2AX ( $\gamma$ -H2AX) is a marker of DNA double-strand breaks<sup>18</sup>. Exposed cells (1 week with 10  $\mu$ M of compound) were plated in a 12-well cell culture treated plate at 1x10<sup>5</sup> cells/well. Following 24 hours incubation at 37°C in media containing 10  $\mu$ M of compound, cells were fixed with a cold 1:1 solution of methanol and acetone for 20 min at -20°C. The

cells were subsequently washed with PBS and blocked for 2 hours at room temperature with 1 mL of
BlockAid<sup>™</sup> Blocking Solution (Thermo Scientific). Each well was stained with a 1:1000 dilution of rabbit
anti-phospho-H2AFX (Millipore Sigma, St. Louis, MO) in PBS overnight at 4°C with gently rocking.
Following multiple washing steps with PBS, cells were incubated with 5 µg/mL of anti-rabbit Alexa Fluor
647-conjugated antibody (ThermoFisher) for 1 hour at room temperature. Cells were subsequently
washed with PBS and stained with 1 µg/mL of Hoechst 33342 (ThermoFisher) for 5 min at room
temperature. Fluorescent images were acquired on an Evos FL Imaging System (ThermoFisher).

186

## 187 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in cellular supernatant

Determination of 8-OHdG content in cellular supernatant was assed using an in-house competition 188 ELISA. Clear 96-well plates were coated with 8-Hydroxy-2'-deoxyguanosine (BioVision, Milpitas, CA) 189 190 overnight at 4°C. Plates were then washed three times with PBS. Cell supernatant in PBS or standard 191 8-OHdG standard curve dilutions were added to the appropriate wells. Rabbit anti-8-OHdG (Abcam, 192 Cambridge, MA) was subsequently added at a 1:2500 final dilution in PBS and the plate was incubated at room temperature with shaking for 2 hours. Following three washes with PBS, anti-rabbit HRP 193 antibody was added at a 1:5000 dilution and the plate was incubated at room temperature with shaking 194 195 for 1 hour. Immediately following five rapid PBS washes, 3.7mM o-phenylenediamine in 0.05 M phosphate-citrate buffer containing 0.03% sodium perborate was added and the plate was incubated at 196 room temperature protected from light for 30 minutes. Absorbance at 405 nm was then measured on a 197 198 Synergy H1 Hybrid Multi-Mode Reader (BioTek).

199

### 200 Clinical validation of urine oxidative DNA damage in HIV/TB patients

201 Study setting and subjects

202 We conducted a prospective cohort study of isoniazid pharmacokinetics among HIV/TB patients at 22 203 public clinics and Princess Marina Hospital in Gaborone, Botswana. The study population has been

204 previously described<sup>19</sup>. Eligibility criteria included citizens of Botswana, HIV infected adults (21 years of

age or older) naïve to ART therapy, and newly diagnosed with pulmonary TB initiated on standard firstline TB regimens at weight-based dosing bands recommended in accordance with WHO guidelines.
The study visit occurred between 5 and 28 days after initiation of first-line TB therapy that included
isoniazid, prior to initiation of ART therapy.

209

```
210 Data collection
```

211 After an overnight fast, the anti-TB drugs were directly administered. Blood samples (10 mL) were 212 drawn at 0, 0.3, 0.9, 2.2, 4.5, and 8 hours post-dosing, based on optimal sampling theory to estimate 213 isoniazid pharmacokinetic parameters. Plasma isoniazid concentrations were measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods as previously described. The peak 214 plasma concentration (C<sub>max</sub>) was obtained directly from the concentration-versus-time data), model-215 216 predicted isoniazid concentrations were used to estimate the area under the concentration-versus-time 217 curve during a 24-hour interval (AUC<sub>0-24</sub>). A spot urine sample (approximately 50 mL) was collected 4 218 hours following anti-TB drug dosing and frozen at -80C until analysis. We measured urinary concentrations of 8-OHdG, a marker of oxidative DNA damage that is stable in cryopreserved urine 219 220 samples, normalized to urine creatinine. The DNA Damage Competitive ELISA kit (ThermoFisher 221 Scientific) was performed using a 1:4 dilution of urine-to-assay buffer. The manufacturer's instructions were followed with one modification to the protocol. Antigen binding was performed overnight at 4°C 222 223 with shaking in lieu of a 2-hour incubation at room temperature. Each assay was performed in triplicate. 224 Optical absorption was assessed using a Synergy H1 Hybrid Multimode Reader (BioTek). To obtain 225 creatinine concentrations for all urine, the Creatinine Urinary Detection Kit (ThermoFisher Scientific) 226 was performed according to the manufacturer's instructions using a 1:20 dilution of urine-to-deionized 227 water.

228

229 Pharmacogenetic genotyping for NAT2 and GST family genes

230 DNA from whole blood samples was used to perform whole exome sequencing as previously 231 described<sup>19</sup>. Individuals with any combinations of the following NAT-2 alleles: 2\*4, 2\*11, 2\*12 and 2\*13, were classified rapid acetylators, while those with both combination of these alleles: 2\*5, 2\*6, 2\*7 and 232 233 2\*14, were considered slow acetylators, in accordance with existing literature<sup>20</sup>. Patients who 234 possessed one allele from the former group and another from the later were classified as intermediate acetylators. Patients whose single-nucleotide polymorphism (SNP) calls were not available in public 235 236 databases (http://nat.mbg.duth.gr/ and http://NAT-2pred.rit.albany.edu/) or published literature were 237 designated as ambiguous. We evaluated allele frequencies in SNPs corresponding to GST family genes based on previously identified clinical associations with oxidation/reduction status or isoniazid 238 hepatotoxicity, including GSTA2, GSTP1, and GSTM1<sup>21,22</sup>. Based on a previously published 239 classification scheme<sup>23</sup>, we categorized GSTA2 haplotypes according to four SNPs (rs2180314, 240 241 rs6577, rs2234951, rs1803682), as shown in Supplementary Table 3. 242 243 Statistical analysis

244 Pharmacokinetic analyses were performed in Phoenix 8.0 (Certara USA, Inc., Princeton, NJ), and

245 physiologically based pharmacokinetic modeling was performed GastroPlus v9.7 (SimulationsPlus,

Redwood City, CA). Multivariate regression modeling was performed in Stata v13 (College Station, TX:

247 StataCorp LP). Plots were generated in GraphPad Prism version 7.00 for Windows (GraphPad

248 Software, La Jolla, CA, <u>www.graphpad.com</u>). Statistical significance was declared for p-values less

- than 0.05.
- 250

#### 251 **RESULTS**

252 Pharmacokinetic exposures to isoniazid and its metabolites in TB patients

253 We obtained parent-metabolite pharmacokinetic data from 10 isoniazid-treated patients, including 4

254 patients with latent TB infection and 6 patients with active TB disease. The properties of the HPLC-

255 MS/MS plasma assays for isoniazid and metabolites are included in Supplementary Table 2. The

256	spaghetti plots of pharmacokinetic profiles are shown in Figure 2 for isoniazid (Figure 2a),
257	acetylisoniazid (Figure 2b), hydrazine (Figure 2c), and acetylhydrazine (Figure 2d). For isoniazid,
258	acetylisoniazid, and acetylhydrazine, all concentrations were greater than the lower limit of
259	quantification, corresponding to 1 ng/mL, 10 ng/mL, and 10 ng/mL for isoniazid, acetylisoniazid, and
260	acetylhydrazine, respectively. For hydrazine, 6 of 60 concentrations (10%) were below the lower limit of
261	quantification, corresponding to 2 ng/mL. As expected, plasma $AUC_{0-24}$ exposures for isoniazid and
262	hydrazine were highly correlated ( $R^2 = 0.78$ ), consistent with the role of NAT2 enzyme in the
263	metabolism of each compound (Figure 1).
264	
265	The physiologically based pharmacokinetic model of isoniazid and metabolite distribution into tissue is
266	included in Supplementary Figure 1. Based on this model, we predicted ratios of liver tissue:plasma
267	exposures for isoniazid, acetylisoniazid, hydrazine, and acetylhydrazine as shown in Table 1. The
268	model predicted an 18-fold higher liver tissue exposure for hydrazine compared to plasma, but lower
269	liver tissue exposures for parent compound and the other metabolites compared to plasma. Based on
270	these model-predicted liver tissue exposures, we selected the concentration of 10 uM to study in pre-
271	clinical toxicodynamic models for all compounds, corresponding to an AUC $_{0-24}$ of 240 uM*hr. This molar
272	concentration fell within 1 log-10 for the median exposure to each compound.
273	
274	Long-term exposures of HepG2 cells treated at clinically relevant concentrations of isoniazid and
275	metabolites
276	Biochemical assays of redox imbalance and mitochondrial injury
277	There was no appreciable cytotoxicity and of isoniazid or its metabolites (Figure 3a). However, we

observed thiol depletion in treated cells over the 28-day exposure period, demonstrating impaired

279 cellular capacity to maintain the oxidation-reduction equilibrium, greatest among hydrazine-treated cells

- 280 (Figure 3b). TMRM is a cell-permeant dye that accumulates in active mitochondria with intact
- 281 membrane potential and is depleted with free radical injury to mitochondrial membrane potential. Figure

3c shows that there was TMRM depletion in all treated cells across 28 days of exposure, with the greatest depletion observed for hydrazine. Furthermore, Figure 3d shows that cellular ATP production was impaired at 28 days of treatment across all experiments, again with the greatest impairment observed for hydrazine as compared with the other compounds.

286

## 287 Microscopic and biochemical assays of oxidative DNA damage

288 We examined levels of oxidative DNA damage in treated HepG2 cells in several ways. First,

289 CometChip microscopy demonstrated greater levels of DNA damage in cells treated for 1 week with

hydrazine, acetylhydrazine, and acetylisoniazid, as compared to isoniazid (Figure 4a). Next, we

291 measured γ-H2AX in treated cells, a variant histone which corresponds to the presence of double-

292 stranded DNA breaks. Following a 1-week exposure period, γ-H2AX levels were greatest during

treatment with hydrazine, as compared to isoniazid, acetylisoniazid, and acetyhydrazine (Figure 4b).

Finally, we examined cellular supernatant levels of 8-OhDG, a measure of oxidative DNA damage that

is stable in cryopreserved clinical samples<sup>24</sup>. Figure 4c shows that the highest increase in 8-OhDG

levels in cell supernatant was with hydrazine treatment. Given that the 10 µM concentration used in

these experiments was less than predicted in liver tissue for hydrazine, but greater than predicted for

isoniazid and non-hydrazine metabolites, these findings collectively supported our hypothesis that

299 hydrazine is the primary mediator of redox imbalance in hepatocytes.

300

#### 301 Oxidative DNA damage among isoniazid-treated TB patients

To further test the clinical relevance of these in vitro findings, we collected urine samples obtained in a previously conducted clinical pharmacokinetic study of HIV/TB patients,<sup>19</sup> to test for 8-OhDG concentrations, a stable marker of oxidative DNA damage, which has been linked to exposures to toxins such as cadmium<sup>25</sup>, chromium, and lead<sup>26</sup> in other patient cohorts. Demographic, clinical, and immunologic characteristics of study participants are shown in Table 2, which shows that none of the characteristics differed *NAT2* genotype. However, *NAT2* genotype was associated with urine 8-OhDG

308 concentrations, as shown in Figure 5a. In unadjusted analysis, we observed a significant increase in 309 urine oxidative DNA damage among patients with slow NAT2 genotypes, compared to rapid acetylator genotypes (p=0.04). Next, we examined GSTA2, which encodes the dominant GST protein in human 310 311 livers, and demonstrates population variability that corresponds to varying levels of hepatic GST 312 expression<sup>22</sup>. The rs2234951 and rs1803682 variants were not detected in the study cohort, while the 313 SNPs rs6577 and rs2180314 were in complete linkage disequilibrium. Accordingly, all haplotypes were 314 either GSTA2\*B or \*C under the naming schema proposed by Tetlow *et a* $\beta^3$  (Supplementary Table 3). We identified 25 patients with the homozygous GSTA2\*B/\*B haplotype (rs6577/rs6577), 12 patients 315 with the GSTA2\*C/\*B haplotype (rs6577/rs2180314), and 2 patients with the homozygous GSTA2\*C/\*C 316 haplotype (rs2180314/rs2180134). In unadjusted analysis, GSTA2 genotype (GSTA2\*C/\*B or 317 GSTA2\*C/\*C versus GSTA2\*B/\*B) was associated with urine oxidative DNA damage, as shown in 318 319 Figure 5b (p=0.03). In contrast, neither the GSTP1 rs1695 variant, previously identified as a predictor of 320 isoniazid toxicity in a Chinese cohort<sup>21</sup>, nor the GSTM1 null variant were associated with urine oxidative DNA damage; however the number of patients with the GSTM1 null variant was small (n=3). 321

322

323 Next, we examined the relationship between isoniazid pharmacokinetic exposures and urine oxidative 324 DNA damage in a multivariate linear regression model. Based on our a priori criteria for model inclusion (greater than 20% change in the regression coefficient when the confounder was included in the 325 326 model), the final multiple linear regression model included the confounding effects of body weight and 327 renal function on the association between isoniazid C<sub>max</sub> and urine oxidative DNA damage (Table 3). 328 Although not a significant confounder of this relationship, we included the effects of GSTA2 genotype (\*B/\*B vs \*C/\*B or \*C/\*C) based on its independent association with urine levels of oxidative DNA 329 330 damage in unadjusted analysis. The corresponding increase in adjusted R-squared with sequential 331 variable inclusion, along with the decline in Akaike information criteria (AIC) score, provided statistical 332 support for choosing model as variables were added. Variance inflation factors for the variables in the final model were 1.31, 2.38, 1.78, and 1.39 for isoniazid C<sub>max</sub>, body weight, creatinine clearance, and 333

GSTA2 genotype, respectively, supporting the absence of significant co-linearity among modelpredictors.

336

Figure 5c is a marginal regression plot of isoniazid  $C_{max}$  and urine oxidative DNA damage, with effect modification by *GSTA2* genotype. Although the graphical relationship suggests that *GSTA2* genotype acts both as an independent predictor as well as an effect modifier of the relationship between isoniazid  $C_{max}$  and urine oxidative DNA damage, the difference in slopes did not reach the *a priori* threshold for statistical significance (p=0.12 for interaction term).

342

#### 343 **DISCUSSION**

Despite being a cornerstone of TB therapy for 60 years, there is considerable uncertainty regarding the 344 mechanism for isoniazid hepatotoxicity, and the host factors that place TB patients at greatest risk. We 345 346 first characterized plasma exposures to isoniazid and its metabolites (acetylisoniazid, hydrazine, and acetylhydrazine) in a clinical pharmacokinetic study, demonstrating that isoniazid and hydrazine plasma 347 348 exposures are highly correlated. Based on these clinical data, we predicted liver tissue exposures using physiologically based pharmacokinetic modeling, observing that hydrazine concentrates in liver relative 349 to plasma. We then developed a long-term, low-exposure experimental set-up in HepG2 cells in order 350 351 to replicate parent-metabolite pharmacologic exposures in the liver during the course of isoniazid treatment. We found that the greatest levels of mitochondrial injury and oxidative DNA damage 352 occurred with hydrazine treatment at equimolar concentrations. Finally, In a clinical translation of this 353 observation, we observed that peak isoniazid serum concentrations and GSTA2 genotype were 354 355 independently associated with increasing urine levels of oxidative DNA damage.

356

These findings link pharmacokinetic exposures to hydrazine, an isoniazid metabolite, with downstream effects on redox imbalance, adding to prior clinical studies of predictors of isoniazid hepatotoxicity. Slow

359 acetylators of isoniazid, as defined by NAT2 genotype, have an increased risk of hepatotoxicity 360 compared to intermediate or rapid acetylators, possessing one or two rapid NAT2 alleles, respectively<sup>27</sup>. In a prior clinical study, peak serum isoniazid concentrations were directly correlated 361 with elevations in liver transaminases, a marker of hepatic inflammation<sup>28</sup>. Future work should identify 362 363 whether early markers of oxidative stress among isoniazid-treated patients, such as the urine measure 364 of DNA damage identified in this clinical study, are predictive of subsequent hepatotoxicity events. For 365 example, a cross-sectional study among isoniazid-treated TB patients in India demonstrated an 366 association between hepatotoxicity events and co-incident measurements of plasma oxidative stress markers<sup>12</sup>. 367

368

The GSTA2 gene encodes a protein sub-unit of  $\alpha$ -GST, the predominant GST enzyme expressed in 369 370 human liver tissue<sup>23</sup>. Previously published data demonstrated decreased  $\alpha$ -GST expression in liver 371 tissue among individuals either heterozygous or homozygous for the GSTA2\*C allele, suggesting greater vulnerability to oxidative hepatic injury<sup>22</sup>. Consistent with this observation, we found that the 372 GSTA2 \*C haplotype, either heterozygous or homozygous, was an independent predictor of urine 373 oxidative DNA damage among HIV/TB patients. In contrast, we observed no relationship between urine 374 375 oxidative DNA damage and the rs1695 allele in GSTP1, previously linked to anti-TB drug toxicity among Chinese patients<sup>21</sup>, or the null mutant GSTM1. 376

377

The involvement of glutathione pathways in the development of isoniazid hepatotoxicity could identify both preventive and therapeutic strategies. Hydrazine cellular effects include inhibition of complex II of the electron transport chain, leading to accumulation of ROS that overwhelms cellular glutathione stores, and directly damaging to DNA through free radical injury<sup>29</sup>. N-acetylcysteine, clinically used to counter acetaminophen toxicity, has also been used for glutathione deficiency in a wide range of conditions<sup>30</sup>. Identification of intermediary signals on the pathway towards clinical hepatotoxicity events,

such as oxidative DNA damage, would also improve efficiency of future clinical trial design of novel TB
 drug therapies, as isoniazid may be included in these investigational drug combinations<sup>3</sup>.

386

Aside from hepatotoxicity, oxidative DNA damage during isoniazid treatment may have additional 387 388 downstream consequences. DNA damage signals induce the nuclear activity of poly(ADP-ribose) polymerase-1 (PARP-1), which is involved in DNA repair activities through multiple pathways<sup>31</sup>. Chronic 389 390 PARP-1 activation competes for intracellular NAD+, resulting in impaired mitochondrial ATP production and cellular apoptosis<sup>32</sup>. Thus, when considering the clinical implications of increased markers of 391 392 oxidative DNA damage, additional effects aside from hepatotoxicity events should be considered. For example, isoniazid treatment has been linked to increased markers of cellular apoptosis in immune 393 cells, and direct effects of isoniazid on the patient's immune-metabolism has been suggested. 394 395 Intriguingly, isoniazid treatment in mice induced apoptosis markers in CD4+ T cells<sup>33</sup>. Future clinical studies should directly compare isoniazid and metabolite pharmacokinetic exposures with 396 397 toxicodynamic markers of redox imbalance, including urine markers of oxidative DNA damage.

398

This clinical and translational study of redox imbalance related to isoniazid and its metabolites had 399 400 several important limitations. Rather than directly measure concentrations in liver tissue, we used physiologically based pharmacokinetic models to estimate liver tissue exposures for each compound. In 401 402 the clinical validation study, the metabolite concentrations were not measured, and thus we cannot 403 directly evaluate the relationship between metabolite exposures (such as hydrazine) and oxidative 404 stress in this clinical cohort. Based on our pre-clinical observations, we hypothesize that hydrazine 405 exposures, rather than isoniazid exposures, would demonstrate the greatest association with urine 406 oxidative DNA damage among isoniazid-treated TB patients. Furthermore, we did not perform 407 prospective serial monitoring of hepatic transaminases in the clinical cohort, and the significance of 408 increased urine oxidative stress markers during isoniazid treatment remains uncertain. Prospective studies of oxidative stress markers, particularly the urine measure of oxidative DNA damage identified 409

in this study, will be essential to unravel the link between isoniazid and metabolite exposures,

411 hepatocellular oxidative stress, and clinical hepatotoxicity events.

412

413 This study had several strengths. Unlike many earlier studies, we examined physiologically relevant 414 isoniazid and metabolite concentrations, supported by a parent-metabolite clinical pharmacokinetic study and physiologically-based pharmacokinetic modeling<sup>34</sup>. We *in vitro* experiments to provide a 415 416 mechanistic link between physiologic exposures to these compounds and cellular signals for redox 417 imbalance and oxidative DNA damage. In this approach, we identified a marker of oxidative DNA 418 damage, 8-OHdG, which was strongly induced by hydrazine exposures in the cell model, which we then related to isoniazid pharmacokinetic exposures and GSTA2 genotype in a clinical study. The 419 420 identification of a urine-based biomarker of oxidative stress related to pharmacokinetic exposures 421 and/or patient genotype supports non-invasive sampling strategies in future prospective studies of 422 isoniazid toxicity. The feasibility of this future work is enhanced by the potential for point-of-care detection of 8-OHdG in paper-based devices<sup>35</sup>. 423

424

In summary, the hydrazine metabolite of isoniazid was the strongest inducer of redox imbalance and downstream oxidative DNA damage in HepG2 cells over long-term exposures to clinically relevant concentrations. In a study of isoniazid-treated TB patients, peak serum isoniazid concentrations and *GSTA2* genotype were independently associated with urine levels of 8-OHdG, a marker of oxidative DNA damage. Future clinical studies should evaluate urine 8-OHdG as an early predictor of clinical hepatotoxicity during isoniazid treatment.

431

432 <u>Funding</u>: CV was supported by NIAID (K23AI102639, R01AI137080).

<u>Ethics statement</u>: The institutional review boards of the University of Pennsylvania, Botswana Ministry
 of Health, and the Princess Marina Hospital approved the clinical study. All participants provided written
 informed consent.


436

#### 437 **FIGURE LEGENDS**

- 438 **Figure 1.** Metabolic pathway of isoniazid.
- 439 **Figure 2.** Plasma concentration-time exposures of isoniazid and its metabolites. <u>Figure 2a</u>. Isoniazid.
- 440 <u>Figure 2b</u>. Acetylisoniazid. <u>Figure 2c</u>. Hydrazine. <u>Figure 2d</u>. Acetylhydrazine. <u>Figure 2e</u>. Correlation of
- 441 isoniazid and hydrazine AUC<sub>0-24</sub>.
- 442 Figure 3. Mitochondrial injury and glutathione depletion in HepG2 cells treated with isoniazid and
- 443 metabolites over 28 days. Figure 3a. Cytotoxicity. Figure 3b. Free thiol assay. Figure 3c. Mitochondrial
- 444 membrane integrity. <u>Figure 3d</u>. ATP production.
- Figure 4. DNA damage markers in HepG2 cells treated with isoniazid and metabolites. Figure 4a.
- 446 Comet chip microscopy of DNA damage after 7 days exposure. Figure 4b. Percentage of DNA in comet
- tail for isoniazid and metabolites after 7 days exposure. Figure 4c. Levels of phosphorylated gamma-
- 448 ph2Ax levels in HepG2 cells after 28 days exposure. Figure 4d. 8-OhDG levels in cellular supernatant
- following 28 days exposure.
- 450 **Figure 5**. Urine levels of oxidative DNA damage among HIV/TB patients, grouped by NAT2 and GSTA2
- 451 genotypes. Figure 5a. NAT2 genotype and urine oxidative DNA damage. Figure 5b. GSTA2 genotype
- 452 and urine oxidative DNA damage. <u>Figure 5c</u>. Margins plot of interaction between isoniazid C<sub>max</sub> and
- 453 GSTA2 genotype. Each line represents marginal predicted levels of oxidative DNA damage for varying
- 454 isoniazid C<sub>max</sub>, according to GSTA2 genotype, and the shaded areas represent 95% confidence
- 455 intervals. Solid line: *GSTA2\*B/\*B*; dashed line: *GSTA2\*C/\*B* or \*C.

Figure 1. Metabolic pathway of isoniazid<sup>36</sup>. Reproduced with permission. 456

457



- 459 Figure 2. Plasma concentration-time exposures of isoniazid and its metabolites among 10 isoniazid-
- 460 treated patients. Black line/triangles: active TB patients; grey line/circles: latent TB patients.

Figure 2a. Isoniazid.





Figure 2b. Acetylisoniazid.



# Figure 2c. Hydrazine.





Figure 2d. Acetylhydrazine.



**Figure 3**. Redox imbalance and mitochondrial impairment in HepG2 cells treated with isoniazid and metabolites over 28 days.

Figure 3a. Overall cytotoxicity.





Figure 3b. Free thiol availability assay.






Figure 3c. Mitochondrial membrane integrity.

Figure 3d. ATP production.




Figure 4. DNA damage markers in HepG2 cells treated with isoniazid and metabolites.





Figure 4a. CometChip representative images after 1-week exposure.

Figure 4b. Percentage of DNA in comet tail for isoniazid and metabolites after 7 days exposure.







Figure 4c. Levels of phosphorylated y-ph2Ax levels in HepG2 cells.






Figure 5. Urine levels of oxidative DNA damage among isoniazid-treated HIV/TB patients.






Figure 5a. Univariate association with NAT2 genotype (p=0.04).

Figure 5b. Univariate association with GSTA2 genotype (p=.03).



<u>Figure 5c</u>. Margins plot of interaction between isoniazid  $C_{max}$  and *GSTA2* genotype in determining levels of urine oxidative DNA damage in the multivariate linear regression model.



Compound	Observed median (range) of plasma AUC <sub>0-24</sub> (uM*hr)	Predicted ratio of liver/plasma	Predicted median liver
		AUC <sub>0-24</sub>	AUC <sub>0-24</sub> (uM*hr)
Isoniazid	60.5 (28.4, 269.4)	0.72	43.6
Acetylisoniazid	157.6 (72.2, 349.8)	0.72	113.5
Hydrazine	14.5 (3.0, 27.8)	18.08	262.2
Acetylhydrazine	66.6 (43.2, 198.0)	0.79	52.6

Table 1. Predicted liver tissue exposures	of isoniazid and metabolites.
---	-------------------------------


Table 2. Characteristics of HIV/TB patients, stratified	ed by NAT2 genotype.
---	----------------------

Characteristic	Slow NAT2	Intermediate NAT2	Rapid NAT2	P-value	
	genotype (N=7)	genotype (N=20)	genotype (N=13)		
Median age (years) (range)	30 (24 - 44)	32 (25 - 48)	32 (24 - 49)	0.54	
Male sex (%)	2 (29%)	11 (55%)	9 (69%)	0.22	
Median body weight (kg)	55.0 (44.0 - 67.0)	54.8 (37.3 - 77.0)	55.0 (42 - 60.5)	0.64	
(range)					
Median creatinine clearance	100.9 (85.3 - 129.6)	107.2 (68.4 - 141.3)	98.4 (40.1 - 157.6)	0.69	
(mL/min) (range)					
Number of current smokers	0 (0%)	1 (5%)	2 (15%)	0.40	
(%)					
Number with positive AFB	4 (57%)	15 (79%)	9 (69%)	0.53	
sputum smear (%)					
Median CD4+ T cell count	252 (208 - 486)	238 (36 - 501)	209 (11 - 735)	0.69	
(cells/mL <sup>3</sup> ) (range)					
Median HIV viral load	2.5x10 <sup>4</sup>	1.1x10 <sup>5</sup>	1.3x10 <sup>5</sup>	0.72	
(copies/mL) (range)	(1.6x10 <sup>3</sup> -7.0x10 <sup>6</sup> )	(86 - 5.1x10 <sup>6</sup> )	(4.3x10 <sup>3</sup> - 1.8x10 <sup>6</sup> )		

**Table 3.** Linear regression model of predictors of urine oxidative DNA damage among isoniazid-treatedHIV/TB patients.

Characteristic	Unadjusted regression P-value		Adjusted regression	P-value
	coefficient (95% CI)		coefficient (95% CI)	
Age (years)	-0.013 (-0.067, 0.041)	0.63		
Sex		0.36		
Male (n=)	Reference			
Female (n=)	0.391 (-0.464, 1.247)			
Body weight (kg)	-0.004 (-0.055, 0.047)	0.88	-0.094 (-0.164, -0.026)	0.01
Creatinine clearance (mL/hr)	0.010 (-0.011, 0.031)	0.35	0.020 (-0.005, 0.045)	0.11
Positive AFB sputum smear	-0.449 (-1.396, 0.498)	0.34		
Days of TB treatment	0.004 (-0.029, 0.038)	0.80		
CD4+ T cell count (cells/mL <sup>3</sup> )	0.001 (-0.002, 0.003)	0.48		
Log HIV viral load	-0.009 (-0.193, 0.175)	0.92		
CRP	0.014 (-0.012, 0.040)	0.28		
Log IL-6	-0.001 (-0.009, 0.008)	0.85		
Isoniazid pharmacokinetic ex	posures			
Isoniazid C <sub>max</sub> (mg/L)	0.153 (-0.060, 0.366)	0.15	0.241 (0.020, 0.462)	0.03
Isoniazid log AUC <sub>0-24</sub>	0.474 (-0.272, 1.221)	0.21		
Pharmacogenetic variability	1			<u> </u>
NAT2 genotype		0.12		
Rapid (n=13)	Reference			
Intermediate (n=20)	0.616 (-0.311, 1.544)			
Slow (n=7)	1.241 (0.033, 2.449)			

GSTA2 genotype				
GSTA2*B/*B (n=25)	Reference			
GSTA2*B/*C (n=12) or	0.971 (0.131, 1.810)	0.03	1.259 (0.321, 2.198)	0.02
GSTA2*C/*C (n=2)				
GSTP1 SNP rs1695		0.34		
WT/WT (n=5)	Reference			
WT/Var (n=26)	0.848 (-0.359, 2.054)			
Var/Var (n=8)	0.469 (-0.965, 1.902)			
GSTM1 null genotype (n=3)	-0.819 (-2.415, 0.777)	0.31		



Supplementary Figure 1. Physiologically-based pharmacokinetic model of isoniazid and metabolites.

Supplementary Table 1. Parameters used in the physiologically-based pharmacokinetic model of

isoniazid and metabolites.

Tissue Compartment	Volume	Simulated K <sub>p</sub>			
	(L)	Isoniazid	Acetylisoniazid	Hydrazine	Acetylhydrazine
Lung	1.14	0.72	0.70	14.31	0.79
Arterial supply	2.11	0	0	0.00	0.00
Venous return	4.22	0	0	0.00	0.00
Adipose	21.00	0.17	0.17	1.55	0.18
Muscle	23.96	0.66	0.64	6.48	0.73
Liver	1.53	0.67	0.65	16.54	0.74
Spleen	0.17	0.70	0.67	11.96	0.77
Heart	0.33	0.71	0.69	8.71	0.78
Brain	1.49	0.70	0.69	2.68	0.77
Kidney	0.35	0.70	0.67	18.06	0.76
Skin	2.73	0.66	0.65	5.43	0.71
Reproductive organs	0.05	0.70	0.68	18.06	0.77
Red marrow	1.07	0.41	0.41	3.00	0.43
Yellow marrow	2.97	0.17	0.17	1.55	0.18
Rest of body	2.50	0.70	0.68	11.96	0.77

Analyte	Lower limit of quantification (LLOQ, ng/mL)	Limit of detection (LOD, ng/mL)	Inter-day variability (% Bias)	Intra-day variability (% Bias)
Isoniazid	1	0.8	3.0	-1.6
Acetylisoniazid	10	6.4	2.0	2.1
Hydrazine	2	0.4	-3.0	-8.5
Acetylhydrazine	10	2.0	-3.5	-3.4

**Supplementary Table 3.** GSTA2 haplotype designations based on SNPs, according to naming schema proposed by Tetlow *et al.* The rs2234951 and rs1803682 variants were not detected in the patient cohort; rs6577 and rs2180314 were in complete linkage disequilibrium.

GSTA2	rs2234951	rs2180314	rs1803682	rs6577
haplotype	(P110S)	(S112T)	(K196N)	(A210C)
GSTA2*A	-	-	-	-
GSTA2*B	-	-	-	+
GSTA2*C	-	+	-	-
GSTA2*D	-	-	+	-
GSTA2*E	+	-	-	-

# REFERENCES

1. Hayashi PH, Fontana RJ, Chalasani NP, et al. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 2015;13:1676-82 e1.

2. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.

3. Wallis RS. Sustainable tuberculosis drug development. Clin Infect Dis 2013;56:106-13.

4. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-6.

5. Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini-review. J Appl Toxicol 2015;35:1427-32.

6. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol 2015;4:180-3.

7. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv 2010;10:98-111.

8. Roth AD, Lee MY. Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays. Biomed Res Int 2017;2017:9176937.

9. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.

10. Friedman JR, Nunnari J. Mitochondrial form and function. Nature 2014;505:335-43.

Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now.
 Br J Clin Pharmacol 2016;81:1030-6.

12. Chowdhury A, Santra A, Kundu S, et al. Induction of oxidative stress in antitubercular druginduced hepatotoxicity. Indian J Gastroenterol 2001;20:97-100.

13. Yew WW, Chang KC, Chan DP. Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. Antimicrob Agents Chemother 2018;62.

14. Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87.

15. Tomanek L. Proteomic responses to environmentally induced oxidative stress. J Exp Biol 2015;218:1867-79.

16. Mandavilli BS, Janes MS. Detection of intracellular glutathione using ThiolTracker violet stain and fluorescence microscopy. Curr Protoc Cytom 2010;Chapter 9:Unit 9 35.

17. Ge J, Prasongtanakij S, Wood DK, et al. CometChip: a high-throughput 96-well platform for measuring DNA damage in microarrayed human cells. J Vis Exp 2014:e50607.

18. Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S. DNA damage foci: Meaning and significance. Environ Mol Mutagen 2015;56:491-504.

19. Vinnard C, Ravimohan S, Tamuhla N, et al. Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. Br J Clin Pharmacol 2017;83:801-11.

20. Doll MA, Hein DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001;288:106-8.

21. Wu S, Wang YJ, Tang X, et al. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. PLoS One 2016;11:e0157478.

22. Ning B, Wang C, Morel F, et al. Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics 2004;14:35-44.

23. Tetlow N, Liu D, Board P. Polymorphism of human Alpha class glutathione transferases. Pharmacogenetics 2001;11:609-17. 24. Frijhoff J, Winyard PG, Zarkovic N, et al. Clinical Relevance of Biomarkers of Oxidative Stress. Antioxid Redox Signal 2015;23:1144-70.

25. Pizzino G, Bitto A, Interdonato M, et al. Oxidative stress and DNA repair and detoxification gene expression in adolescents exposed to heavy metals living in the Milazzo-Valle del Mela area (Sicily, Italy). Redox Biol 2014;2:686-93.

26. Pawlas N, Olewinska E, Markiewicz-Gorka I, et al. Oxidative damage of DNA in subjects occupationally exposed to lead. Adv Clin Exp Med 2017;26:939-45.

27. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to antituberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012;16:589-95.

28. Cojutti P, Duranti S, Isola M, et al. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? J Antimicrob Chemother 2016;71:1323-

9.

29. Runge-Morris M, Wu N, Novak RF. Hydrazine-mediated DNA damage: role of hemoprotein, electron transport, and organic free radicals. Toxicol Appl Pharmacol 1994;125:123-32.

30. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355-9.

31. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010;39:8-24.

32. Fang EF, Scheibye-Knudsen M, Brace LE, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 2014;157:882-96.

33. Tousif S, Singh DK, Ahmad S, et al. Isoniazid induces apoptosis of activated CD4+ T cells: implications for post-therapy tuberculosis reactivation and reinfection. J Biol Chem 2014;289:30190-5.

34. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos 2015;43:1823-37.

35. Martins GV, Tavares APM, Fortunato E, Sales MGF. Paper-Based Sensing Device for Electrochemical Detection of Oxidative Stress Biomarker 8-Hydroxy-2'-deoxyguanosine (8-OHdG) in Point-of-Care. Sci Rep 2017;7:14558.

36. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing

enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 2011;25:803-

12.